GlassScriptPhysician profile
Michael Nissenbaum
NPI 1912288218
$23,023.98
in general payments reported to CMS, 2019-2025
64 companies · $3,449 in 2025
The $3,449 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,547 · 2020: $2,196 · 2021: $3,075 · 2022: $3,043 · 2023: $4,083 · 2024: $3,631 · 2025: $3,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,162.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,157.48 | 2021-2025 | |
| Medtronic, INC. | $2,211.59 | 2021-2025 | Linq II, Micra, Percept PC Brainsense |
| Sk Life Science, INC. | $1,425.07 | 2020-2025 | |
| Ucb, INC. | $1,165.46 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Pfizer INC. | $1,164.76 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $1,154.86 | 2019-2025 | Ingrezza, Ongentys |
| Amgen INC. | $893.67 | 2019-2025 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $771.11 | 2021-2025 | Hyqvia, Gammagard Liquid |
| Medtronic Vascular, INC. | $766.28 | 2019 | |
| Grifols USA, LLC | $715.46 | 2019-2025 | Gamunex-C |
| Eisai INC. | $644.81 | 2021-2025 | |
| Genzyme Corporation | $587.38 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $569.08 | 2019-2022 | |
| Allergan, INC. | $470.87 | 2019-2022 | |
| Lundbeck LLC | $455.17 | 2020-2025 | Vyepti, Rexulti |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nissenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.